Table 3.
Gene expression associates with clinical outcomes.
Gene expression | P value | Association with clinical outcome | Pathways involved with IBD |
---|---|---|---|
↑ IRGM | P = 0.001 | Medical treatment response to aminosalicylates (5-ASAs) | Autophagy |
↑ FOXO4 | P = 0.05 | Histological remission | Immune response |
↑ CTLA4 | P = 0.05 | Histological activity index score | |
↓ SLC26A3 | P = 0.001 | Clinical course: the course of the same initial activity and prolonged remission | Solute transport |
↑ SLC39A4 | P = 0.0007 | Evolution: tendency to years of evolution of between 10 and 15 years | |
↑ SOD2 | P = 0.00004 | Severe histological activity | Oxidative stress |
↑ TDO2 | P = 0.06 | Clinical course: characterized by the presence of initial activity and then prolonged remission more than 5 years | |
↑ ALDOB | P = 0.005 | Evolution: early age at diagnosis of less than 40 years | Carbohydrate metabolism |
↑ ALDOB | P = 0.005 | Clinical course: prolonged benign clinical course characterized by the presence of higher initial activity and remission at 5 years |